NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis $2.32 -0.20 (-7.94%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.23 -0.09 (-3.84%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NRx Pharmaceuticals Stock (NASDAQ:NRXP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NRx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.26▼$2.5450-Day Range$2.32▼$3.5052-Week Range$1.10▼$6.01Volume569,458 shsAverage Volume495,042 shsMarket Capitalization$45.96 millionP/E RatioN/ADividend YieldN/APrice Target$28.50Consensus RatingBuy Company Overview NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. Read More NRx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreNRXP MarketRank™: NRx Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 398th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingNRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNRx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about NRx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NRx Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.80% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NRx Pharmaceuticals has recently decreased by 23.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.80% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NRx Pharmaceuticals has recently decreased by 23.09%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.09 News SentimentNRx Pharmaceuticals has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.12 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for NRx Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest22 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 633% compared to the previous 30 days.MarketBeat Follows6 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.27% of the stock of NRx Pharmaceuticals is held by institutions.Read more about NRx Pharmaceuticals' insider trading history. Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXP Stock News HeadlinesNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $28.50 Average Target Price from Analysts3 hours ago | americanbankingnews.comNRx Pharmaceuticals announces expanded access policy for NRX-100August 27, 2025 | msn.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer. | Timothy Sykes (Ad)NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)August 27, 2025 | globenewswire.comNRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old ProblemAugust 27, 2025 | theglobeandmail.comD. Boral Capital Remains a Buy on NRX Pharmaceuticals (NRXP)August 27, 2025 | theglobeandmail.comBTIG Sticks to Its Buy Rating for NRX Pharmaceuticals (NRXP)August 27, 2025 | theglobeandmail.comNRx Pharmaceuticals price target raised to $25 from $21 at BTIGAugust 25, 2025 | msn.comSee More Headlines NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed this year? NRx Pharmaceuticals' stock was trading at $2.20 at the beginning of the year. Since then, NRXP shares have increased by 5.5% and is now trading at $2.32. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its earnings results on Monday, August, 18th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.67. Read the conference call transcript. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals's stock reverse split before market open on Tuesday, April 2nd 2024.The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are NRx Pharmaceuticals' major shareholders? NRx Pharmaceuticals' top institutional shareholders include AdvisorShares Investments LLC (1.53%), Geode Capital Management LLC (1.00%), Marshall Wace LLP (0.19%) and Group One Trading LLC. Insiders that own company stock include Daniel C Javitt, Jonathan C Javitt, Chaim Hurvitz, Aaron Gorovitz, Stephen H Willard and Patrick John Flynn. View institutional ownership trends. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), GE Aerospace (GE) and Disc Medicine (IRON). Company Calendar Last Earnings8/18/2025Today9/02/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRXP CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Price Target for NRx Pharmaceuticals$28.50 High Price Target$46.00 Low Price Target$18.00 Potential Upside/Downside+1,128.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.13 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-550.94% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.48) per share Price / Book-1.57Miscellaneous Outstanding Shares19,810,000Free Float16,046,000Market Cap$45.96 million OptionableOptionable Beta1.63 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NRXP) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredSell this, buy thatI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.